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Introduction
Critically ill patients who require exogenous organ support as a result of  severe physiologic insult are at 
high risk of  secondary infections (1). Critical illness may arise from a variety of  sterile or infectious insults. 
However, despite its varied etiology, critical illness is often accompanied by stereotyped immune dysregu-
lation, with features of  both hyperinflammation and immune-mediated organ damage, as well as impair-
ment of  antimicrobial functions (2–4). Critical illness is estimated to cause 58 million adult deaths per year 
globally (5), and although much of  the mortality is attributable to the underlying condition, secondary 
infections make a significant contribution to the eventual outcome (5–8).
Impairment of  immune cell function predicts secondary infection (2, 9–11), and the failure of  neutro-
phil phagocytosis and bacterial killing has been demonstrated to be one of  the strongest predictors of  these 
infections. A key driver of  the functional impairment of  neutrophils is the anaphylatoxin C5a (12–14). 
However, there remain no efficacious treatments for critical illness–induced immune dysfunction in part 
because the mechanisms that underpin C5a-induced dysfunction are incompletely understood.
A wealth of  data has demonstrated the importance of  C5a in driving classical inflammatory events in 
neutrophils, including chemotaxis (15, 16), generation of  ROS (14, 17, 18), phagocytosis (19, 20), degran-
ulation (21, 22), and delayed apoptosis (23–25). One of  the key questions in this area is how to explain 
the divergent findings of  C5a being not only a critical cofactor in phagocytosis (19, 20) but also capable of  
suppression of  phagocytosis in sepsis and critical illness (12–14). In critical illness, dysregulated activation 
Critical illness is accompanied by the release of large amounts of the anaphylotoxin, C5a. C5a 
suppresses antimicrobial functions of neutrophils which is associated with adverse outcomes. The 
signaling pathways that mediate C5a-induced neutrophil dysfunction are incompletely understood. 
Healthy donor neutrophils exposed to purified C5a demonstrated a prolonged defect (7 hours) 
in phagocytosis of Staphylococcus aureus. Phosphoproteomic profiling of 2712 phosphoproteins 
identified persistent C5a signaling and selective impairment of phagosomal protein phosphorylation 
on exposure to S. aureus. Notable proteins included early endosomal marker ZFYVE16 and V-ATPase 
proton channel component ATPV1G1. An assay of phagosomal acidification demonstrated C5a-
induced impairment of phagosomal acidification, which was recapitulated in neutrophils from 
critically ill patients. Examination of the C5a-impaired protein phosphorylation indicated a role for 
the PI3K VPS34 in phagosomal maturation. Inhibition of VPS34 impaired neutrophil phagosomal 
acidification and killing of S. aureus. This study provides a phosphoproteomic assessment of 
human neutrophil signaling in response to S. aureus and its disruption by C5a, identifying a defect in 
phagosomal maturation and mechanisms of immune failure in critical illness.
2insight.jci.org   https://doi.org/10.1172/jci.insight.137029
R E S E A R C H  A R T I C L E
of  the complement and coagulation cascades occurs, leading to exposure of  neutrophils to high concen-
trations of  C5a (4, 26–29). In these circumstances, we and others have shown that C5a reduces neutrophil 
phagocytosis and ROS production in both rodent models and critically ill patients (12–14, 30). Further, 
C5a exposure has been shown to be associated with nosocomial infection, organ failure, and increased 
mortality in critically ill patients (2, 12, 13, 30–32).
Although several signal-mediating aspects of  C5a-induced neutrophil dysfunction have been estab-
lished (13, 14, 21), a global picture of  signaling in neutrophils encountering common pathogens and how 
this process is perturbed by C5a does not exist. Such studies are challenging in neutrophils owing to their 
high degradative enzyme content and short in vitro survival times (33).
This study aimed to characterize the neutrophil phosphoprotein response to a common nosocomi-
al pathogen, Staphylococcus aureus, and investigate how this is perturbed by prior exposure to C5a. Our 
differential phosphoprotein analysis implicated C5a in altered phagosomal maturation, findings that we 
confirmed with functional neutrophil assays in C5a-treated healthy donor cells and those from critically 
ill patients. The phosphoprotein response to S. aureus implicated the involvement of  the PI3K VPS34, and 
hence we continued examined the effects of  this enzyme on phagosomal maturation.
Results
C5a induces a prolonged defect in neutrophil phagocytosis of  bacteria. C5a induces a defect in phagocytosis of  
the clinically relevant bacterial species S. aureus (Figure 1A) and E. coli (Figure 1B). Pulse exposure of  
neutrophils to C5a revealed a persistent defect in phagocytosis lasting at least 7 hours (Figure 1C), with 
short pulses inducing a significant defect. These effects were not explained by the loss of  cell viability 
(Figure 1D). A similar prolonged defect was identified in the whole blood assay (Figure 1E), representing 
continuous exposure of  neutrophils to C5a (which cannot be washed off  in this assay). The ability of  
C5a to inhibit phagocytosis was dependent on the temporal relationship between C5a and S. aureus expo-
sure. Only preexposure to C5a induced the defect in phagocytosis, whereas coexposure or the addition of  
C5a 30 minutes after S. aureus addition failed to induce a defect (Figure 1F). In a dose titration, we could 
not identify any dose that enhanced phagocytosis; instead we found progressive decrease in phagocytosis 
as concentration of  C5a was increased (Supplemental Figure 1A; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.137029DS1).
To explore the potential mechanisms whereby preexposure to S. aureus prevents the inhibitory effect 
of  C5a, we examined whether this could be due to reduced C5aR1 expression. Although we could demon-
strate a reduction in C5aR1 after S. aureus exposure (Supplemental Figure 1B), this was modest and sim-
ilar to the reductions induced by other inflammatory mediators including LPS and leukotriene A (LTA), 
neither of  which ameliorated the subsequent suppressive effect of  C5a (Supplemental Figure 1C). Further, 
C5a — and not LPS, LTA, GM-CSF, and TNF — reduced neutrophil phagocytosis (Supplemental Figure 
1D). To confirm the functional relevance of  C5a-impaired phagocytosis, we demonstrated that C5a pre-
treatment reduced bacterial killing of  S. aureus (Supplemental Figure 1E).
Given the temporal dependence of  the inhibitory effect of  C5a, we examined whether prior exposure to 
S. aureus enhanced or impaired subsequent ingestion. Using sequential exposure of  whole blood to S. aureus 
labeled with 2 different pHrodo probes, we demonstrated that neutrophils that ingest the first target are more 
likely to ingest the second target (Supplemental Figure 2A), whereas progressive increase in the first target 
revealed a fundamental limit on the capacity of  neutrophils to ingest (Supplemental Figure 2, B and C).
S. aureus and C5a induce widespread changes in the neutrophil phosphoproteome. Although key signaling 
“nodes” have been identified in neutrophils after C5a exposure (12, 13), no map of  global signaling net-
works has been produced. Given the rapidity of  the C5a-induced phagocytic impairment demonstrated 
above, and the known signaling kinetics of  GPCRs (34), we examined posttranslational modification by 
phosphorylation (i.e., a phosphoproteomic approach).
In total, 4859 proteins and 2712 phosphoproteins were identified in peripheral blood neutrophils 
obtained from 4 healthy volunteers. C5a-induced suppression of  phagocytosis in these donors was con-
firmed (Supplemental Figure 3A), and technical reproducibility was high (Supplemental Figure 3, B–E) 
with the magnitude of  phosphorylation changes within the previously reported range (35). Changes in the 
human proteome were minimal (2% of  total proteome with S. aureus treatment), whereas phosphoprotein 
expression varied markedly (31.6% of  total phosphoproteome with S. aureus treatment, Supplemental 
Table 1). Figure 2 shows the top 25% most variable phosphoproteins, which demonstrates the significant 
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effect these stimuli have on neutrophil signaling. The phosphoproteomic and proteomic data sets are pub-
licly available in the PRIDE database (https://www.ebi.ac.uk/pride/ reference PXD017092).
C5a exposure induces persistent alteration in phosphoproteins across several pathways. Figure 3A shows a volca-
no plot comparing neutrophils treated with C5a versus vehicle control. 119 proteins were significantly differ-
entially phosphorylated at 1 hour, indicating persistent signaling, consistent with the prolonged inhibition 
of  phagocytosis seen in Figure 1. Notably, C5aR1 remained highly phosphorylated (a modification key to 
its internalization) (36), and this change has been used to identify C5a-exposed, dysfunctional neutrophils 
(2, 12, 13, 37–39). Pathway enrichment using Metascape (40) indicated involvement of  pathways including 
membrane trafficking, regulated exocytosis (degranulation), and phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) signaling, which persist 1 hour after stimulation with C5a (Figure 3B). Given the finding of  a tem-
poral dependency of  C5a exposure on phagocytosis (Figure 1F), we examined how the phosphoproteomic 
alterations after C5a compared with those after S. aureus. The pathways showing prolonged activation after 
C5a exposure overlap with those induced by S. aureus (Supplemental Figure 4A), and many of  the proteins 
are common to both conditions (Supplemental Figure 4B).
S. aureus induces a marked alteration in the phosphoproteome, which is significantly affected by C5a exposure. 
Exposure of  neutrophils to S. aureus induced a marked alteration in the phosphoproteome (Figure 4A); 
863 proteins (31% of  the phosphoproteome) significantly alter their phosphorylation status. Pathway 
enrichment indicated the involvement of  multiple pathways, notably Rho-GTPase signaling, endosomal 
transport, degranulation, and actin cytoskeleton organization (Figure 4B, with extended heatmap show-
ing top 100 pathways shown in Supplemental Figure 5).
C5a exposure before S. aureus reduced the phosphoprotein response to the bacterium considerably 
(Figure 4C). However, comparing C5a and control treated cells exposed to S. aureus, 19 proteins were 
Figure 1. C5a induces a prolonged defect in neutrophil phagocytosis of bacteria. (A and B) Isolated neutrophils were pretreated with 100 nM C5a or vehicle 
control for 60 minutes before incubation with S. aureus (A) or E. coli (B) bioparticles (5 μg/mL). Data are presented as the median phagocytic index for each 
condition for n = 7 (A) or 6 (B) independent experiments. *P = 0.016 (A) and 0.031 (B) by Wilcoxon’s matched-pairs signed-rank test. (C) Neutrophils were 
pulsed with C5a (100 nM) or PBS control for the indicated periods of time and then washed 2 times. S. aureus bioparticles (5 μg/mL) were then added and 
cells were incubated for the indicated time points. Data are presented as the mean plus or minus SD of the phagocytic index of C5a-treated cells relative to 
their paired vehicle control for n = 5 independent experiments. P < 0.0001 for time and P = 0.0186 for treatment by 2-way ANOVA. ***P = 0.0001 ****P < 
0.0001 by Dunnett’s multiple comparison test. (D) Data are presented as the mean plus or minus SD of the percentage of DRAQ7 positive, dead cells for n = 
5 independent experiments. P = 0.378 for time and P = 0.349 for treatment by 2-way ANOVA. (E) Anticoagulated whole blood was pretreated with 300 nM 
C5a or control for the indicated duration before phagocytosis was measured as previously indicated. Data are presented as the mean plus or minus SD of 
the cumulative phagocytic index for n = 4 independent experiments. P < 0.0001 by 2-way ANOVA, ****P < 0.0001, ***P < 0.001 by Holm-Šidák’s multiple 
comparisons test. (F) S. aureus bioparticles (15 μg/mL) were incubated with isolated PMNs in the presence of C5a (100 nM) or PBS added at the indicated 
time points, with time 0 representing the time of addition of S. aureus bioparticles. Experiments proceeded for the indicated time points and phagocytic 
index quantified. Data are presented as the mean plus or minus SD of the phagocytic index of C5a-treated cells relative to their paired vehicle control for n = 
5 independent experiments. P < 0.0001 for time and P = 0.0186 for treatment by 2-way ANOVA. ****P < 0.0001 by Dunnett’s multiple comparisons test.
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identified, suggesting selective pathway modulation (Figure 4D). When mapped to known pathways 
using Metascape (40) and manually annotated from the Uniprot database (41), a pattern of  reduced 
phosphorylation of  phagosomal maturation proteins (Table 1) and pathways (Figure 4E) emerged. 
Notably, early endosomal marker ZFYVE16 and its interactor TOM1 had impaired phosphorylation 
after C5a exposure, as did V-type ATPase subunit G1 (ATP6V1G1, which is critical for phagosomal 
acidification). ZFYVE16 requires phosphatidylinositol-3-phosphate (PI3P) for recruitment to the pha-
gosome (42). Another prominent PI3P-responsive protein noted was Ras-related protein 7a (RAB7A), 
although this protein was not differentially phosphorylated between the C5a/S. aureus and vehicle con-
trol/S. aureus conditions. Supplemental Figure 6 shows individual donor data for these key proteins.
Our data set suggests that C5a exposure that precedes pathogen encounter prevents effective signaling 
through the phagosomal maturation pathways and links intracellular signaling to the prolonged functional 
impairment noted in this context. The other major cluster of differentially phosphorylated proteins comprised 
nuclear and nuclear membrane proteins, many of which are involved in mitosis and nuclear envelope integrity.
C5a induces an impairment in phagosomal acidification, distinct from the impairment in ingestion. The 
phosphoproteomic signature of  altered phagosomal maturation afterC5a exposure and the involvement of  
V-ATPase suggested that C5a had effects beyond impaired ingestion of  bacteria. To disentangle the effects of  
phagocytic ingestion and phagolysosomal acidification, S. aureus bioparticles colabeled with the pH-insen-
sitive dye AF488 and pHrodo red were used. Neutrophils ingested particles and then subsequently acidified 
the phagosome, a process which could be ablated by the addition of  the V-ATPase inhibitor bafilomycin (43) 
(Figure 5, A and B). The use of  this dual-labeled probe in time series experiments demonstrated that the 
processes of  ingestion and phagosomal acidification are distinct (Supplemental Figure 7A). Addition of  the 
weak base ammonium chloride at the end of  the assay reduced the pHrodo signal, confirming the indicator 
measured changes in phagosomal pH independently of  particle internalization (Supplemental Figure 7B), 
whereas live cell imaging demonstrated a progressive increase in pHrodo signal with time as phagosomes 
Figure 2. S. aureus and C5a induce 
widespread changes in the neutrophil 
phosphoproteome. Neutrophils were 
isolated from n = 4 healthy donors, 
pretreated with C5a (100 nM) or 
control before addition of pHrodo S. 
aureus bioparticles (15 μg/mL). Cells 
were allowed to phagocytose for 15 
minutes before being snap frozen and 
processed for proteomic analysis as 
detailed in Methods. A heatmap of 
phosphoprotein intensity relative to 
baseline (log2FC) across the 4 experi-
mental conditions shows phosphopro-
teins with variance across conditions  
in the top 75th percentile with dendro-
grams clustered by Euclidean distance. 
Increased phosphoprotein expression 
is indicated in red, decreased in blue. 
Only phosphoproteins detected in all  
4 donor samples were included.
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were acidified without further particle ingestion (Supplemental Figure 7, C–E, and Supplemental Video 
1). C5a pretreatment increased the proportion of  neutrophils that failed to ingest particles (Figure 5C) and 
increased the population that ingested particles but failed to acidify the phagosome (Figure 5D). Recent 
reports suggest that C5a induces Na+/H+ exchanger-1–mediated (NHE-1-mediated) cytoplasmic alkalini-
zation (21). An NHE-1 inhibitor did not alter the C5a-mediated effect on phagosomal acidification (Figure 
5E), suggesting that the pathways mediating these 2 effects of  C5a on neutrophils are distinct. Furthermore, 
we confirmed previous work (14) showing C5a impaired ROS production (Supplemental Figure 8), which in 
combination with the current findings, suggests C5a induces a generalized failure of  phagosomal maturation 
in addition to its effect on phagocytic ingestion.
VPS34 inhibition impairs phagosomal acidification. The differential phosphoprotein analysis (Table 1) and 
phagosomal acidification assays (Figure 5) demonstrated impaired phagosomal maturation after exposure 
to C5a. As noted, several of  the phosphoproteins that were differentially phosphorylated are known inter-
actors with PI3P. The PI3K VPS34 is the dominant source of  PI3P in mammalian cells (44). Although 
VPS34 itself  was detected, its phosphorylation status was not significantly altered. However, the finding 
that C5a altered the phosphorylation status of  PI3P-responsive proteins led us to explore the role of  
VPS34 in phagosomal acidification. We used the selective inhibitor, VPS34IN1 (45), to examine the role 
of  this enzyme in phagosomal acidification, and how this related to the defect induced by C5a. VPS34IN1 
did not alter the percentage of  neutrophils that underwent phagocytosis (Figure 6A and time course in 
Figure 6E), but it did lead to a reduction in the overall number of  particles ingested (Figure 6B) and a 
more marked reduction in pHrodo signal (Figure 6C and time course in Figure 6F), indicating VPS34IN1 
impairs phagosomal acidification. VPS34 inhibition also led to an impairment in the killing of  S. aureus 
(Figure 6D), similar to that observed with C5a (Supplemental Figure 1D) but without a significant reduc-
tion in phagosomal ROS production (Supplemental Figure 9).
Neutrophils from critically ill patients exhibit defective phagosomal acidification. To establish the relevance 
of  our findings to the clinical setting, we used our assay of  phagosomal acidification to interrogate neu-
trophils obtained from critically ill patients and healthy volunteers. We assessed neutrophil function in 
Figure 3. C5a exposure induces per-
sistent alteration in phosphopro-
teins across several pathways. 
Experimental conditions were as 
outlined in Figure 2. (A) Volcano 
plot comparing phosphoprotein 
intensity between C5a-treated and 
control-treated cells, before phago-
cytosis. Proteins with adjusted P 
values less than 0.05 are shown in 
blue and proteins of interest (dis-
cussed in text) are labeled. P values 
were computed by limma-based 
linear models with Bonferroni’s 
correction for multiple testing. (B) 
Metascape (40) enrichment heat-
map showing functional clusters of 
phosphoproteins dephosphorylated 
(DP) and phosphorylated (P) after 
C5a treatment.
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critically ill patients, defining neutrophil dysfunction as phagocytosis of  less than 50% in our previously 
established zymosan assay (Figure 7A), a threshold associated with a markedly increased risk of  noso-
comial infection (12, 13, 46). Reduced internalization of  S. aureus particles was also evident in patients 
with dysfunctional neutrophils identified in this manner (Supplemental Figure 10). Using our phagosomal 
acidification assay, we compared patients with dysfunctional neutrophils with critically ill patients with 
functional neutrophils and healthy controls. Dysfunctional neutrophils exhibited a failure of  phagosomal 
acidification (Figure 7B) that was not seen in patients with functional neutrophils. Consistent with pre-
vious work (2, 12), we observed a correlation between C5aR1 expression (decreased after C5a exposure) 
and phagocytosis (Figure 7C) and an inverse correlation between C5aR1 expression and phagosomal acid-
ification (Figure 7D), though the latter correlation did not reach statistical significance. The patients with 
dysfunctional and functional neutrophils could not be readily identified by clinical factors such as severity 
of  illness or precipitating insult (Supplemental Table 2). These data provide evidence of  dysfunctional 
phagosomal acidification in critically ill patients and imply a role for C5a in driving this dysfunction.
Discussion
Our data demonstrate that C5a induces both a prolonged defect in phagocytosis of  relevant pathogens 
(S. aureus and E. coli) and a persistent signaling across multiple pathways for some hours after the well 
characterized initial signaling events such as ionized calcium flux (47) and PIP3 generation (48). This 
Figure 4. S. aureus induces a marked alteration in the phosphoproteome that is significantly affected by C5a 
exposure. Experimental conditions were as outlined in Figure 2. (A, B, and D) Proteins with adjusted P values 
less than 0.05 are shown in blue and proteins of interest (discussed in text) are labeled. Volcano plots compare 
phosphoprotein intensity between the conditions specified in the figure. P values were computed by limma-based 
linear models with Bonferroni’s correction for multiple testing. (C) Metascape (40) enrichment heatmap showing 
functional clusters of phosphoproteins dephosphorylated (DP) or phosphorylated (P) after S. aureus exposure. (E) 
Metascape (40) bar graph showing top nonredundant functional clusters of phosphoproteins enriched in the vehicle 
control/S. aureus condition versus C5a/S. aureus condition.
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finding supports the proposal that persistent C5a-induced signaling may mediate the neutrophil dysfunc-
tion observed in critically ill patients (12, 13).
To our knowledge, the data presented here (Figure 3, Figure 4, and Figure 5) represent the deepest 
assessment of  the human neutrophil proteome and phosphoproteome (49–51). These data provide a 
phosphoproteomic assessment of  the human neutrophil response to S. aureus and C5a. Unlike transcrip-
tomic data (52–54), phosphoproteomics provides a direct assessment of  mediators that are likely to have 
Table 1. Differentially phosphorylated proteins between C5a and control-treated neutrophils exposed to 
S. aureus
Protein name Subcellular localization Functional role
Endosomal/phagosomal
Zinc finger FYVE domain-containing 
protein 16 (ZFYVE16) Early Endosomes
PI(3)P binding FYVE domain, found 
on early endosomes, targets TOM1  
to endosomes
Target of Myb protein 1 (TOM1) Endosomes/azurophil granule membrane (neutrophil) Known interactor with ZFYVE16
V-type proton ATPase subunit G 1 
(ATP6V1G1) Endosomes/phagosomes
Proton channel acidifying vacuolar 
structures
Wiskott-Aldrich syndrome protein, 
WASp (WAS) Cytoplasm, phagosomes
RhoGTPase effector and actin 
polymerisation





hydrolase 5 (USP5) Lysosome and cytoplasm Deubiquitination





Nuclear pore complex protein 
(NUP153) Nuclear membrane
Phosphorylation occurs during 
nuclear membrane disassembly
Lamin-B1 (LMNB1) Nuclear membrane Phosphorylation occurs during nuclear membrane disassembly
Histone H3.3 (H3F3A) Nucleus Histone protein
Protein SGT1 homolog (SUGT1) Nucleus and kinteochore Mitosis
Sperm-associated antigen 7 (SPAG7) Nucleus Nucleic acid binding
Splicing factor U2AF 35 kDa subunit 
(U2AF1) Nucleus RNA splicing
Chromatin complexes subunit BAP18 
(BAP18) Nucleus Chromatin organization
Nuclear/Cytoplasmic proteins
Serine/threonine-protein kinase 3 
(STK3) Nucleus/cytoplasm
Cycles between nucleus and 
cytoplasm, influenced by 
phosphorylation status under  
control of caspases
Transforming acidic coiled-coil-
containing protein 1 (TACC1)
Nucleus, centerosome,  
microtubules




Regulation of actin cytoskeleton and 
MAP kinase activity
Endoplasmic reticulum
Endoplasmic reticulum junction 
formation protein lunapark (LNP) Endoplasmic reticulum Phosphorylated during mitosis
Thioredoxin-related transmembrane 
protein 1 (TMX1) Endoplasmic reticulum Cell response to oxidative stress
All 19 phosphoproteins with Bonferroni’s adjusted P values less than 0.05 for difference in phosphorylation status 
between the Control plus S. aureus versus C5a plus S. aureus conditions. Subcellular location and function manually 
annotated from Uniprot database (41).
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functional implications, especially in short-lived cells such as neutrophils (33, 55) and early pathogen 
exposure time points, as examined in this study.
The marked changes observed in phosphoproteins in response to S. aureus are perhaps unsurprising, 
as the response to and clearance of  bacteria are primary functions of  neutrophils. Many of  the pathways 
identified (Figure 4 and Supplemental Figure 4) are consistent with established literature on neutrophil 
responses to S. aureus, and indeed other bacteria, including activation of  PI3K (56), toll-like receptor sig-
naling (57), and neutrophil degranulation (58).
The enrichment of  PI3K and Rho GTPase signaling on C5a stimulation are in keeping with our previous 
identification of  key roles for these molecules in C5a-mediated functional deficits in neutrophils (12, 13, 59). 
The marked suppression of  the phosphorylation response to S. aureus induced by C5a pretreatment is not 
simply a response to reduced particle ingestion. Fifteen minutes after pathogen contact, there were limited 
differences in the ingestion rates between C5a and control treatments, and these became more marked over 
time (Figure 1). Furthermore, the differential analysis of  C5a/S. aureus versus vehicle control/S. aureus con-
ditions identified defects in specific signaling pathways, most notably those involving endosomal trafficking. 
This led us to examine the process of  phagosomal maturation and to identification of  a C5a-induced failure 
of  phagosomal acidification (Figure 5) with similar findings in critically ill patients (Figure 7). Neutrophil 
phagolysosomes have been demonstrated to undergo a biphasic change in pH with early alkalinization at 3–5 
minutes providing optimal conditions for protease activation (60–62), followed by progressive acidification. 
Our data are consistent with the later acidification demonstrated by these studies, though we did not specifi-
cally assess early time points with probes calibrated to measure exact pH. Failure of  phagosomal maturation 
Figure 5. C5a induces an impairment in phagosomal acidification, distinct from the impairment in ingestion. (A) Exemplar flow cytometry plots of 
whole blood pretreated with vehicle control or bafilomycin A (100 nM, 60 minutes) before exposure to colabeled AF488/pHrodo red S. aureus (5 μg/mL) for 
120 minutes. Both phagocytosis (x axis) and phagosomal pH (y axis) can be measured simultaneously in the same population of cells. pHrodo fluorescence 
increases with decreasing pH, indicating phagosomal maturity as shown. (B) Conditions as in A. Data are shown as individual data points with mean for 
n = 7 individual donors. P = 0.016 by Wilcoxon’s test. (C) Whole blood was pretreated with vehicle control or C5a (300 nM, 60 minutes) before exposure to 
phagocytosis probe (5 μg/mL) for 180 minutes. Phagocytosis without maturation (i.e., AF488 signal) is shown. Data are shown as mean plus or minus SD 
of n = 5 individual donors. ****P < 0.0001 by 2-way repeated-measures ANOVA with Bonferroni’s multiple comparisons test. (D) Conditions as in C. The 
percentage of S. aureus particle positive (AF488+) cells with low pH (mature) and high pH (immature) phagosomes is shown for control and C5a-treated 
conditions. Data are shown as mean plus or minus SD of n = 5 individual donors. ***P < 0.001 by repeated-measures 2-way ANOVA with Bonferroni’s mul-
tiple comparisons test. (E) Whole blood was pretreated with C5a (300 nM, 60 minutes), NHE-1 inhibitor (5 μM), or both, then exposed to maturation probe 
for 60 minutes. The percentage of AF488+ cells with high pH (immature) phagolysosomes is shown. Data are shown as mean plus or minus SD from n = 7 
individual donors. P = 0.0080 by Friedman’s test, *P < 0.05 for Dunn’s test of multiple comparisons, ns = nonsignificant.
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and intracellular killing has been described in primary immune deficiency (63), but it has not previously been 
described as part of  the immunoparesis of  critical illness. Impaired phosphorylation in pathways involving 
nuclear envelope breakdown and nuclear pore disassembly by C5a was unanticipated. The functional relevance 
of  these changes remains unclear, though they may be early processes in the formation of  nonlethal DNA- 
containing neutrophil extracellular traps (64).
Important signaling proteins involved in the process of  phagosomal maturation (such as RAB7A, 
TOM1, and ZFYVE16) can be recruited to the phagosomal membrane by PI3P produced predominantly by 
VPS34 (42, 65, 66). Both ZFYVE16 and TOM1 phosphorylation were impaired by C5a exposure. We inves-
tigated the role of  VPS34 as a mediator of  neutrophil bactericidal function and found that selective VPS34 
inhibition produced a similar impairment in phagosomal acidification to that observed with C5a (Figure 
6). The finding that a similar defect could be induced by inhibiting VPS34, the dominant source of  PI3P in 
neutrophils (44), adds further validation to the pathway signature identified in the phosphoproteomic profile.
Ellson and colleagues (67) demonstrated that PI3P plays an important role in targeting neutrophil 
oxidase components to phagosomal membranes, and its importance in phagosomal maturation has also 
been identified in Dictyostelium discoideum (68), murine macrophages, and macrophage-like cell lines (69). 
However, the role of  VPS34 in human neutrophils has previously been inferred indirectly (70), owing to 
prior lack of  selective inhibitors and the difficulties of  genetically manipulating human neutrophils. Ander-
son and colleagues (70) demonstrated a role for VPS34 in NADPH oxidase –mediated ROS generation in 
neutrophils. We found a nonsignificant reduction in ROS production (Supplemental Figure 9) that was 
much less marked than the effect on phagosomal acidification. The reasons for these divergent findings are 
uncertain, though they may include differences in ROS measurement assays, our use of  a selective VPS34 
inhibitor, and differences between primary human neutrophils and cell lines. The mechanism by which 
Figure 6. VPS34 inhibition impairs phagosomal acidification. Whole blood was pretreated with vehicle control or VPS34IN1 (1 μM, 60 minutes) before 
addition of maturation probe (5 μg/mL) (A–D), or live S. aureus (E), for 120 minutes before analysis. (A) Percentage of neutrophils that phagocytosed 
bioparticles. P = 0.31 by Wilcoxon’s test. n = 6 individual donors. (B) MFI of ingested particles, indicating relative quantity of phagocytosis. *P = 0.03. by 
Wilcoxon’s test. n = 6 individual donors. (C) pHrodo MFI, indicating phagosomal acidification. *P = 0.03. by Wilcoxon’s test. n = 6 individual donors. (D) 
After phagocytosis of live bacteria, human cells were lysed in alkaline dH2O and surviving bacteria were incubated overnight on blood agar. Bacterial sur-
vival was quantified by counting colonies. *P = 0.03 by paired t test, n = 5 individual donors. (E and F) Whole blood was processed as above with quantifi-
cation of phagocytosis (E) and acidification (F) at the indicated time points. There was a reduction in phagosomal acidification as shown but no change in 
percentage of cells that underwent phagocytosis. Data are shown as mean plus or minus SD of n = 5 individual donors. **P = 0.0058 for drug treatment by 
2-way repeated-measures ANOVA with Bonferroni’s multiple comparisons test. 
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VPS34 inhibition impairs killing of  S. aureus requires further investigation, as phagosomal acidification 
is not thought to be critical to this process (71) and it is likely that the enzyme inhibition leads to further 
defects in phagosomal maturation. This study is unable to identify whether C5a prevents phagosomal acid-
ification by inhibiting the recruitment of  ATP6V1G1 to the phagosome or by preventing its function. Our 
data demonstrated that phosphorylation of  the S68 residue of  the V-ATPase G subunit was impaired by 
C5a pretreatment, and we hypothesize this posttranslational modification is critical to its ability to effec-
tively acidify the phagosome. Further work is ongoing to address these issues.
It is intriguing to note that although VPS34 inhibition does not reduce the percentage of  cells that 
phagocytose bacteria (Figure 6A), consistent with previous work (70), it does reduce the number of  par-
ticles ingested (Figure 6B). This is consistent with the finding that ingestion of  an initial target facilitates 
ingestion of  a subsequent target (Supplemental Figure 2), implying a capacitive stage of  phagocytosis. That 
VPS34 inhibition impairs this capacitive phase suggests a hitherto undescribed relationship between phago-
somal maturation and the capacity of  cells to ingest particles.
Our data also demonstrate that the timing of  C5a exposure (before, alongside, or after pathogen 
encounter) has an important effect on neutrophil function. Only preexposure to C5a impaired subsequent 
Figure 7. Neutrophils from critically ill patients exhibit defective phagosomal acidification. (A) Neutrophils purified 
from critically ill patients were exposed to zymosan (5 μg/mL) and allowed to phagocytose for 30 minutes as described in 
Methods and classified as functional or dysfunctional based on a cutoff of 50% of cells phagocytosing greater than or equal 
to 2 zymosan particles as previously described (12, 13). Data are shown as mean plus or minus SD for n = 6 patients with 
dysfunctional neutrophils and 5 patients with functional neutrophils respectively. **P = 0.004 by Mann-Whitney U test. (B) 
Neutrophil phagosomal acidification was assessed in whole blood from critically ill patients using the maturation probe as 
previously described. Patients were classed as dysfunctional using the assay from A. Data are shown as mean plus or minus 
SD n = 6 patients with dysfunctional neutrophils, 5 patients with functional neutrophils, and 10 healthy controls, respec-
tively. P = 0.04 by 1-way ANOVA. **P < 0.01 by Holm-Šidák’s test of multiple comparisons. (C and D) C5aR1 expression was 
assessed by flow cytometry and correlated (Spearman) with phagocytosis (C) and phagosomal acidification (D) for n = 12 
patients. NB: One patient’s cells did not adhere to tissue culture plastic for the zymosan assay, and thus they could not be 
assigned to dysfunctional or nondysfunctional groups shown in A and B. C5aR1 expression and maturation probe data was 
available to allow inclusion in correlation analyses in C and D and hence the difference in numbers between these figures.
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neutrophil phagocytosis (Figure 2). Reduced C5aR1 availability for ligation by C5a is unlikely to explain 
this observation, as C5aR1 downregulation is induced by multiple agents that do not have the same effect 
on phagocytosis (Supplemental Figure 1D). The pathways enriched under C5a conditions are also rep-
resented among those enriched after S. aureus exposure, with all but 8 of  the C5a-induced, significantly 
altered phosphoproteins also being identified after S. aureus exposure. It is therefore plausible that signaling 
induced by S. aureus overwhelms C5a-induced phosphorylation events unless they were established before 
S. aureus exposure. Indeed, the signaling induced by initial ingestion may facilitate subsequent ingestion, 
as identified in the sequential exposure assay (Supplemental Figure 2), actively mitigating against C5a- 
induced suppression. We did not identify a dose at which C5a enhanced phagocytosis in this work (Sup-
plemental Figure 1A), indeed, nor did we in our previous work (12, 13). Collectively, these findings imply 
that the divergent findings on the effect of  C5a on phagocytosis when C5a is added exogenously, as in this 
report or generated by direct addition of  bacteria to blood as reported by Mollnes and colleagues (19, 20), 
are due to the temporal relationship between exposures rather than a biphasic dose–response relationship.
This finding of  distinct temporal responses to C5a suggests that where neutrophils encounter bacte-
ria and C5a at the same time, such as at the site of  infection, the phagocytic response is not impaired. 
When complement activation spills over systemically and C5a exposure precedes neutrophil–bacterial 
interactions — as occurs with systematic inflammation in critical illness and sepsis — dysfunction occurs, 
impairing the host’s ability to respond to invasive infections or subsequent bacterial insults. (2, 38)
This study was conducted entirely in primary human neutrophils, using C5a an established, clin-
ically relevant modulator of  neutrophil function that has been linked to a range of  adverse outcomes 
in critically ill patients. The use of  clinically relevant pathogens and the development of  a whole-blood 
bacteremia model increase the relevance of  our study to the in vivo situation. Impaired ingestion of  
zymosan by neutrophils in patient has been associated with adverse outcomes including development 
of  subsequent nosocomial infection (13). The finding that patients with such impairment also manifest 
impaired phagosomal acidification that correlates with markers of  C5a exposure (Figure 7) and suggests 
that the identified mechanisms may be clinically relevant.
Several potential limitations should be highlighted. The phosphoproteomic response to S. aureus was 
evoked with heat-killed bacterial particles, conjugated with fluorescent dyes, and these may not fully reflect 
the response to live bacteria, although they do allow parallel functional assessment and standardization 
of  the stimulus between donors and across research sites. Although whole blood is more physiologically 
relevant than cell culture media, it remains an abstraction from the situation in vivo, as it must be antico-
agulated and does not involve normal flow or interaction with a vascular endothelium. Furthermore, the 
model may not reflect the function of  neutrophils that have migrated into tissues, where most bacterial 
infections occur. Technical limitations currently prevent efficient phosphoproteomic assessment of  cells 
from whole blood, and therefore isolated cells with the inherent in vitro artefacts must be used.
In conclusion, we have demonstrated the role of  C5a in mediating neutrophil dysfunction in the 
clinically relevant setting of  S. aureus and E. coli bacteremia, and demonstrated that the effects of  C5a can 
persist for many hours and which is dependent on the temporal sequence of  C5a and bacterial exposure. 
We also describe the neutrophil phosphoproteomic response to S. aureus, and to prolonged exposure 
to C5a. This approach identified a defective phagosomal maturation signature induced by C5a, likely 
involving modulation of  Class III PI3K-dependent pathways. Further, we have shown the functional 
manifestation of  this phosphorylation signature in a model of  bacteremia. Finally, the clinical relevance 
of  this failure of  phagosomal acidification was observed in critically ill patients. A deeper understanding 
of  the biology of  neutrophil dysfunction in critical illness is key to developing effective treatments for a 
phenomenon associated with multiple adverse clinical outcomes.
Methods
Supplemental Methods are available online with this article.
Patients and healthy donors. Patients were included if  they were receiving support of  one or more 
organ systems in an intensive care unit and expected to require such support for a further 24 hours and 
not thought likely to die within the next 24 hours. Exclusions were pregnancy, HIV infection, hemato-
logical malignancy, or immunosuppressive medication.
Neutrophil isolation. Neutrophils were isolated from citrated peripheral venous blood by using a 
modification of  the discontinuous plasma/Percoll density gradient centrifugation technique initially 
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described by Böyum in 1968 (72). Further details of  methods and reagents described below are avail-
able in the supplementary materials.
Phagocytosis of  pHrodo S. aureus and E. coli bioparticles by purified neutrophils. Purified human neutro-
phils, suspended in Iscoves Modified Dulbecco’s Medium (IMDM; Life Technologies) with 1% autologous 
serum at a concentration of  5 x 106/mL were incubated in microcentrifuge tubes (Eppendorf) with purified 
human C5a (Complement Technology) or vehicle control. pHrodo-conjugated S. aureus or E. coli bioparti-
cles (Life Technologies) were opsonized in 50% autologous serum for 30 minutes before be being added to 
the suspended cells. Analysis was by flow cytometry (Attune NxT, Thermo Fisher Scientific)
No-wash, no-lyse whole blood assay of  neutrophil phagocytosis and ROS production. Blood, collected into arg-
atroban (150 μg/mL, R&D Systems), was treated with inhibitors or priming agents, as indicated in the 
respective figure legends (Figures 1–3 and 5 and Supplemental Figures 1, 3, and 8), before being exposed 
to S. aureus pHrodo/dihydrorhodamine (CalBiochem) or E. coli pHrodo bioparticles. Aliquots were stained 
on ice with anti-CD16 antibody (clone 3G8, BioLegend) diluted and analyzed by flow cytometry (Attune 
NxT). Where reported, the phagocytic index is the median fluorescence intensity multiplied by the per-
centage of  phagocytosing cells. The concentration of  bioparticles used in each experiment is specified in 
Figures 1, 2, and 5–7 and Supplemental Figures 1, 3, and 7.
In variations on this assay, S. aureus particles labeled with the pH-insensitive dye AlexaFluor AF488 
(Life Technologies) or dual labeled with AF488 and pHrodo red were used. pHrodo red conjugation of  
AF488 S. aureus was performed in-house using the pHrodo Particle Labeling Kit (Thermo Fisher Scientif-
ic). Fluorescence of  extracellular particles was quenched with trypan blue (0.1mg/mL, Life Technologies). 
For experiments with inhibitors including C5a, VPS34IN1, and bafilomycin, the inhibitors were added at 
the concentrations noted in the figure legends for Figures 1–3, 5, and 6 and Supplemental Figures 1, 3, 8, and 
9 for the duration indicated, before exposure to S. aureus. For ammonium chloride phagosomal neutraliza-
tion, cells were exposed to pHrodo red-labeled particles for the duration indicated in Supplemental Figure 
7, then exposed to 15 mM ammonium chloride for 5 minutes before analysis by flow cytometry.
Patient samples, and a comparator group of  healthy donors, were analyzed in a different laboratory 
that did not have access to an Attune Nxt flow cytometer; to fit with established workflows in this labora-
tory, red cells were lysed using Pharmlyse (BD Biosciences) followed by washing twice using a Facswash 
Assistant (BD Biosciences) before undertaking flow cytometry (Fortessa, BD Biosciences).
Bacterial killing assay — whole blood. Methicillin-sensitive S. aureus bacteria (strain ASASM6) were grown to 
early log phase. Blood was collected into argatroban and incubated with bacteria for 1 hour. Human cells were 
lysed by addition of pH 11 distilled water for 3 minutes before plating of serial dilutions on Colombia blood agar.
Neutrophil phagocytosis of  zymosan. Purified human neutrophils (suspended in phenol red-free IMDM 
with 1% autologous serum at a concentration of  106/mL) were allowed to adhere to 24-well tissue culture 
plates (Sarstedt) for 20 minutes. Opsonized zymosan (5 μg/mL, MilliporeSigma) was then added for 30 
minutes, before noninternalized zymosan particles were washed off  with warm IMDM. Plates were incu-
bated at all stages at 37°C in 5% CO2. Plates were allowed to air dry before being fixed with methanol and 
stained with QuickDIFF staining kit (Reagena). Phagocytosis was measured by manual counting of  cells 
under light microscopy. Neutrophils with greater than or equal to 2 internalized zymosan particles were 
counted as a proportion of  total neutrophils in 2 separate fields per well as previously described (12).
Preparation of  whole human neutrophil lysates for phosphoproteomics. Neutrophils were isolated from whole 
blood as detailed above and resuspended in RPMI 1640 media (Thermo Fisher Scientific) containing 10 
Mm HEPES (Thermo Fisher Scientific) with 1% autologous serum at a concentration of  1 × 107 cells/mL.
Proteomic and phosphoproteomic studies. Triplicates of  1 × 107 neutrophils were treated with vehicle 
control or C5a (100 nM, 60 minutes) at 37°C before addition of  pHrodo S. aureus (15 μg/mL). Phagocy-
tosis was allowed to occur for 15 minutes. Aliquots were withdrawn from each triplicate and pooled at 
the indicated time points. Cells were centrifuged at 400 g for 5 minutes at 4°C, supernatants aspirated, 
and cell pellets were snap frozen in liquid nitrogen. Cells were lysed by the addition of  sodium dodecyl 
sulphate (0.5%; MilliporeSigma) and triethylammonium bicarbonate buffer (0.1 M; MilliporeSigma) and 
sonicated, before undergoing centrifugation, trypsin digestion, tandem mass tag labeling, fractionation, 
phosphopeptide enrichment, and liquid chromatography and tandem mass spectrometry analysis. See 
Supplemental Figure 11 for details and experimental schematic.
Statistical analysis of  wet laboratory data. Data are presented as individual data points with summary sta-
tistics (median ± IQR or mean ± SD) according to whether data are normally distributed. Parametric or 
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nonparametric statistical tests were applied as appropriate after data were tested for normality using the 
Kolmogorov-Smirnov test. Tests used for comparisons are indicated in figure legends. Two-tailed P values 
were computed; a P value of  less than 0.05 was considered statistically significant. Statistical analyses were 
undertaken using GraphPad Prism Software v8.0.
Statistical analysis of  phosphoproteomics data. Spectral.raw files from data dependent acquisition were 
processed with the SequestHT search engine on Thermo Scientific Proteome Discoverer 2.1 software. 
Data were searched against both human and S. aureus UniProt reviewed databases at a 1% spectrum–
level FDR criteria using Percolator (University of  Washington, USA). MS1 mass tolerance was con-
strained to 20 ppm, and the fragment ion mass tolerance was set to 0.5 Da. TMT tags on lysine residues 
and peptide N termini (+229.163 Da), and methylthio (+45.988 Da) of  cysteine residues (+45.021 Da) 
were set as static modifications, whereas oxidation of  methionine residues (+15.995 Da) and deamida-
tion (+0.984 Da) of  asparagine and glutamine residues were set as variable modifications. For TMT-
based reporter ion quantitation, we extracted the signal-to-noise ratio for each TMT channel. Parsimo-
ny principle was applied for protein grouping.
Peptide and phosphopeptide intensities were normalized across conditions using median scaling 
and then summed to generate protein and phosphoprotein intensities. Proteins and phosphoproteins 
were independently identified and quantified in all samples from all 4 donors; species not meeting these 
criteria were excluded from subsequent analysis. Log2 fold change was calculated between conditions 
of  interest, compared across n = 4 donors, and tested for statistical significance by limma-based linear 
models with Bonferroni’s correction for multiple testing. Hierarchical clustering using Euclidean dis-
tance was undertaken on the entire data set. Heatmaps and volcano plots were generated as shown in 
Results. Statistical analyses were performed in RStudio (73) using the qPLEXanalyzer (35) package, 
and plots were produced using the ggplot2 (74) package.
Statistics. Tests used were 2-tailed paired t test for comparison of  2 conditions in the same donor 
where data were normally distributed, or Wilcoxon matched pairs for nonnormally distributed data 
from the same donor. Where 2 or more conditions were compared over time in the same donors repeat-
ed measures 2-way ANOVA was used with Dunnet’s, Holm-Sidak’s, or Bonferroni’s post hoc tests. For 
2 or more conditions at a single timepoint from the same donors Friedman’s was used with Dunn’s 
post hoc test. For comparisons between 2 groups of  donors Mann-Whitney U test was used, and for 3 
conditions at a single timepoint from different donors 1-way ANOVA used with Bonferroni’s post hoc 
test.  Correlations were assessed by Spearman’s rho. For phosphoproteomic intensity changes P values 
were calculated by limma-based linear modelling with Bonferroni’s correction for multiple analyses. 
normality testing was conducted using the Kolmogorov-Smirnov test.
Study approvals. Ethical permission for obtaining peripheral venous blood from healthy volunteers was 
provided by the Cambridge Local Research Ethics Committee (REC reference: 06/Q0108/281) and all 
donors provided written, informed consent. Critically ill patient blood samples were obtained under an 
approval granted by the North East-Newcastle & North Tyneside 2 Research Ethics Committee (REC 
reference: 18/NE/0036). Healthy volunteer blood samples for comparison with the critically ill patient 
samples were obtained under the approval granted by the County Durham and Tees Valley Research Ethics 
Committee (REC reference: 12/NE/0121).
Data sharing statement. The mass spectrometry proteomics data have been deposited to the ProteomeX-
change Consortium via the PRIDE (75) partner repository with the data set identifier PXD017092.
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